Table 2.
Clinical experiences with Imatinib.
| References | Design | Type of TGCT | Number of patients on Imatinib | Duration of treatment (median) | Efficiency on symptoms | Stability of the disease | Tolerance |
|---|---|---|---|---|---|---|---|
| Cassier et al. (21) | Clinical series | NA | 29 | 4–7 months | 74% | 73% | 22% of Toxicity |
| Verspoor et al. (12) | Retrospective study | NA | 62 | 9 months | 31% | 65% | 12% stopped treatment for toxicity AE grade 1–2: 78% AE grade 3: 9% |
| Mastboom et al. (22) | Retrospective study | NA | 25 | 7 months | 32% | 63% | 12% stopped treatment for toxicity AE grade 1–2 : 80% AE grade 3 : 12% |
| Brahmi et al. (23) | Retrospective study | NA | 15 | 6 months | 1st line of treatment:11% | 60% | 3 patients stopped treatment because of AE |
| 2nd line: 6% | 14% | ||||||
| 3rd line: 3% | 66% |
NA, not available; TGCT, Tenosynovial Giant Cell Tumors; AE, adverse effects.